Induction treatment of ANCA-associated vasculitis with a single dose of rituximab

Tabitha Turner‐Stokes(Imperial College London), Mark A. Little(Trinity College Dublin), C. Ashley(British Museum), D. Dinneen(The Royal Free Hospital), AD Salama(The Royal Free Hospital), A. J. Howie, Ruth J. Pepper(University College Hospital), Eleanor Sandhu(The Royal Free Hospital), A. Burns(The Royal Free Hospital), Natalie Stolagiewicz(The Royal Free Hospital)
Lara D. Veeken
March 7, 2014
10.1093/rheumatology/ket489
Cited by 29

Related Papers

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
|Annals of the Rheumatic Diseases|2013|454
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
|Nephrology Dialysis Transplantation|2009|156
Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production
|Lara D. Veeken|2008|149
A disease-associated gene desert directs macrophage inflammation through ETS2
|Nature|2024|139
Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis
|Kidney International|2013|105